title: Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
abstract: No series have reported the results of the use of the therapeutic anti-CD20 monoclonal antibody (Rituximab) in the setting of adult refractory/relapsed B-ALL. We report here the outcomes of such nine patients treated at two french institutions by a combination of Rituximab+chemotherapy. We showed that four patients could achieve complete response while four other patients were documented with blast clearance superior to 50% from the baseline in bone marrow. We conclude that our results suggested some efficacy for the use of Rituximab in combination with chemotherapy in the setting of refractory/relapsed adult B-ALL. Larger series within prospective trials are needed to confirm these results.
authors.affiliation: Service d'Hématologie Clinique, CHU Hôtel Dieu, Université de Nantes, Centre d'Investigation Clinique en Cancerologie (CI2C) and INSERM U892, Nantes, France. patrice.chevallier@chu-nantes.fr
authors.forename: Patrice
authors.initials: P
authors.lastname: Chevallier
authors.forename: Arnaud
authors.initials: A
authors.lastname: Pigneux
authors.forename: Nelly
authors.initials: N
authors.lastname: Robillard
authors.forename: Sameh
authors.initials: S
authors.lastname: Ayari
authors.forename: Thierry
authors.initials: T
authors.lastname: Guillaume
authors.forename: Jacques
authors.initials: J
authors.lastname: Delaunay
authors.forename: Marion
authors.initials: M
authors.lastname: Eveillard
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Dumas
authors.forename: Eric
authors.initials: E
authors.lastname: Lippert
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Thibaut
authors.initials: T
authors.lastname: Leguay
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D018951:Antigens, CD20 / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D010865:Pilot Projects; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors; D000069283:Rituximab; D016879:Salvage Therapy; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D003561:Cytarabine; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate